Takeda Pharmaceutical Co Ltd - FY2024 Financial Summary
Business Context and Reporting Period
This Form 6-K filing summarizes the consolidated financial results for Takeda Pharmaceutical Company Limited for the fiscal year ended March 31, 2024. The report was filed on May 9, 2024. Takeda is a global biopharmaceutical company focusing on Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), Oncology, Vaccines, and Neuroscience. The company operates in approximately 80 countries and regions.
Key Financial Metrics
| Metric | FY2024 (Actual) | FY2023 (Actual) | Change (AER) |
|---|---|---|---|
| Revenue | JPY 4,263.8 billion | JPY 4,027.5 billion | +5.9% |
| Operating Profit | JPY 214.1 billion | JPY 490.5 billion | -56.4% |
| Profit Before Tax | JPY 52.8 billion | JPY 375.1 billion | -85.9% |
| Net Profit (Attributable to Owners) | JPY 144.1 billion | JPY 317.0 billion | -54.5% |
| Basic EPS | JPY 92.09 | JPY 204.29 | -54.9% |
| Core Operating Profit | JPY 1,054.9 billion | JPY 1,188.4 billion | -11.2% |
| Core EPS | JPY 484 | JPY 558 | -13.4% |
| Net Cash from Operating Activities | JPY 716.3 billion | JPY 977.2 billion | -26.7% |
| Cash and Cash Equivalents (End of Year) | JPY 457.8 billion | JPY 533.5 billion | -14.2% |
| Total Assets | JPY 15,108.8 billion | JPY 13,957.8 billion | +8.2% |
| Total Bonds and Loans | JPY 4,843.8 billion | JPY 4,382.4 billion | +10.5% |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 5.9% (Actual Exchange Rate) driven by favorable foreign exchange rates and growth in Plasma-Derived Therapies (+20.7%), GI (+11.1%), and Rare Diseases (+6.5%). This was partially offset by declines in Neuroscience (-1.7%) due to generic competition for VYVANSE and a decrease in "Other" revenue (-18.8%) due to the loss of exclusivity for AZILVA.
- Profit Decline: Operating profit fell 56.4% primarily due to JPY 130.6 billion in impairment losses (including JPY 74.0 billion for ALOFISEL and JPY 28.5 billion for EXKIVITY), increased R&D expenses (+15.3%), and higher other operating expenses (+42.2%) driven by restructuring and litigation costs.
- Tax Impact: Net profit was significantly supported by a JPY 91.4 billion income tax benefit, largely due to a JPY 63.5 billion reversal of tax payable related to the settlement of the AbbVie Break Fee tax assessment with Irish Revenue.
- Core Performance: Core Operating Profit decreased 11.2% (AER) and 13.3% (Constant Exchange Rate), reflecting higher costs and investments in pipeline programs despite revenue growth.
Guidance, Outlook, and Risks
Outlook for FY2025 (Ending March 31, 2025)
- Revenue: Forecast at JPY 4,350.0 billion (+2.0% vs FY2024), driven by growth in ENTYVIO, immunoglobulins, and new launches (QDENGA, FRUZAQLA, EOHILIA), offset by continued VYVANSE decline.
- Operating Profit: Forecast at JPY 225.0 billion (+5.1%), benefiting from lower expected impairment charges (JPY 50.0 billion vs JPY 130.6 billion in FY2024) and cost efficiencies.
- Net Profit: Forecast at JPY 58.0 billion (-59.7%), reflecting the absence of the one-time tax benefit recorded in FY2024.
- Management Guidance (CER Basis): Core Revenue expected to be flat to slightly declining; Core Operating Profit expected to decline approx. 10%; Core EPS expected to decline mid-10s%.
Risks and Contingencies
- Generic Competition: Significant headwinds from generic entrants for VYVANSE (ADHD) and DEXILANT (acid reflux), with VYVANSE sales expected to decline 49% at CER in FY2025.
- Litigation: Takeda paid USD 505 million (JPY 26.4 billion loss) in March 2024 regarding the AbbVie supply agreement litigation for LUPRON.
- Restructuring: A new enterprise-wide efficiency program is scheduled to start in FY2025, with estimated one-time restructuring expenses of JPY 140.0 billion.
- FX Volatility: Forecasts assume a weaker Yen (USD 150 JPY vs 144 JPY actual), which provides a favorable translation impact but introduces currency risk.
Investor Verification Checklist
- Impairment Charges: Verify the sustainability of the JPY 130.6 billion impairment charge in FY2024 and the assumption of only JPY 50.0 billion in FY2025.
- VYVANSE Decline: Assess the impact of the projected 49% CER decline in VYVANSE sales on future cash flows and the adequacy of new product launches to offset this loss.
- Tax Normalization: Confirm the impact of the one-time JPY 63.5 billion tax benefit reversal on the FY2025 net profit forecast, which drops significantly despite operating profit growth.
- Restructuring Costs: Review the details of the JPY 140.0 billion restructuring expense planned for FY2025 and its expected impact on operating margins.
- Debt Levels: Monitor the increase in total bonds and loans to JPY 4.84 trillion and the company's ability to service debt amidst lower net profit forecasts.